Text this: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)

  ____     __   __    ______    ______   __   _   
 |  _ \\   \ \\/ //  /_____//  /_   _// | || | || 
 | |_| ||   \ ` //   `____ `    -| ||-  | '--' || 
 | .  //     | ||    /___//     _| ||_  | .--. || 
 |_|\_\\     |_||    `__ `     /_____// |_|| |_|| 
 `-` --`     `-`'    /_//      `-----`  `-`  `-`  
                     `-`